MEDICINE'S DATA GAP: When Labels Mislead; Results of Drug Trials Can Mystify Doctors Through Omission
Quirk in FDA rules allows labels of existing drugs to say nothing about clinical tests that have led FDA to turn down company's application to have drug approved for new use or category of patients; labeling issue is another facet of expanding debate over incomplete disclosure and publication of results of clinical drug trials; doctors worry ambiguous or incomplete drug labels may lead them to prescribe drugs for treatments that FDA-reviewed tests have shown to be ineffective or potentially risky; some drugs tested for pediatric use, with equivocal results, carry labels saying safety and effectiveness has not been established in children; American Academy of Pediatrics and other medical groups are pressing Congress for bill requiring companies to list tests of drugs and medical devices in public database; Rep Henry A Waxman has asked Health Sec Tommy G Thompson to release data from all pediatric drug trials conducted under federal laws that encourage such tests; table of labels that fail to show pediatric trial results; photo (M)
